Marktanalyse - Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016

GlobalData
12.2016
133 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016


Summary


GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.


Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs


Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2016 15

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2016 15

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2016 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2016 18

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19

2.4.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 19

2.4.2 Pfizer Acquires Medivation in Tender Offer 20

2.4.3 Shire Raises USD12.1 Billion in Public Offering of Notes 21

2.4.4 Gilead Sciences Raises USD5 Billion in Public Offering of Notes 21

2.4.5 Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 22

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 23

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2016 23

3.1.1 Top M&A Deals in Q3 2016 24

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2015 - Q3 2016 25

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2016 26

3.2.1 Top Initial Public Offerings in Q3 2016 27

3.2.2 Top Secondary Offerings in Q3 2016 27

3.2.3 Top PIPE Deals in Q3 2016 28

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2015 - Q3 2016 28

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2016 30

3.3.1 Top Venture Financing Deals in Q3 2016 31

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2016 32

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2015 - Q3 2016 33

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2015 - Q3 2016 35

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2016 37

3.4.1 Top Private Equity Deals in Q3 2016 38

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2015 - Q3 2016 39

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2016 40

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2015 - Q3 2016 42

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 44

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2016 45

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2016 46

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 47

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 49

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 50

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 52

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2016 54

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2016 54

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2016 57

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2016 58

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2016 58

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2015 - Q3 2016 59

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 61

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 63

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2015 - Q3 2016 64

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2015 - Q3 2016 66

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 68

6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2015 - Q3 2016 68

6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2015 - Q3 2016 70

6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71

6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2015 - Q3 2016 72

6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2015 - Q3 2016 73

6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 75

7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2016 75

7.1.1 Oncology - Deals of the Quarter 76

7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2016 79

7.2.1 Central Nervous System - Deals of the Quarter 80

7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2016 84

7.3.1 Infectious Disease - Deals of the Quarter 85

7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2016 87

7.4.1 Immunology - Deals of the Quarter 88

7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2016 90

7.5.1 Metabolic Disorders - Deals of the Quarter 91

7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2016 93

7.6.1 Cardiovascular - Deals of the Quarter 94

7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2016 97

7.7.1 Gastrointestinal - Deals of the Quarter 98

7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2016 100

7.8.1 Ophthalmology - Deals of the Quarter 101

7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2016 103

7.9.1 Respiratory - Deals of the Quarter 104

7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2016 107

7.10.1 Dermatology - Deals of the Quarter 108

8 Deal Summary by Geography 111

8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2016 111

8.1.1 North America - Deals of the Quarter 112

8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2016 115

8.2.1 Europe - Deals of the Quarter 116

8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2016 118

8.3.1 Asia-Pacific - Deals of the Quarter 119

8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2016 121

8.4.1 Rest of the World - Deals of the Quarter 122

9 Pharmaceuticals & Healthcare, Global, Top Advisors 124

9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2015 - Q3 2016 124

9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2015 - Q3 2016 126

10 Appendix 128

11 Further Information 130

11.1 Methodology 130

11.2 About GlobalData 131

11.3 Disclosure information 132

11.4 Disclaimer 132





1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 16

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2016 18

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2016 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 24

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2016 24

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2015 - Q3 2016 25

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 27

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2016 27

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2016 27

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2016 28

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 29

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 31

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2016 31

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2016 33

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 34

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 35

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2015 - Q3 2016 36

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 38

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2016 38

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 39

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 41

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 43

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 45

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2016 45

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2016 46

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2016 46

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 48

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 51

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 53

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 55

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 57

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2016 57

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2016 58

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2016 58

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 60

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2015 - Q3 2016 62

Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 65

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 67

Table 39: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2015 - Q3 2016 69

Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2015 - Q3 2016 70

Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71

Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2015 - Q3 2016 72

Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2015 - Q3 2016 73

Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74

Table 45: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 76

Table 46: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 80

Table 47: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 85

Table 48: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 88

Table 49: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 91

Table 50: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 94

Table 51: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 98

Table 52: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 101

Table 53: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 104

Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 108

Table 55: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 112

Table 56: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 116

Table 57: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 119

Table 58: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 122

Table 59: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 125

Table 60: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 127

Table 61: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q3 2015-Q3 2016 128





1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 15

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2016 17

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2016 18

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2015 - Q3 2016 23

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2015 - Q3 2016 25

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 26

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2015 - Q3 2016 28

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 30

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2016 32

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2016 32

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2015 - Q3 2016 33

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 35

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 37

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2015 - Q3 2016 39

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 40

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 42

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 44

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 47

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 49

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2015 - Q3 2016 50

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2015 - Q3 2016 52

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 54

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 56

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 59

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 61

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2015 - Q3 2016 63

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2015 - Q3 2016 64

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2015 - Q3 2016 66

Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2015 - Q3 2016 68

Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2015 - Q3 2016 70

Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2015 - Q3 2016 71

Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2015 - Q3 2016 72

Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2015 - Q3 2016 73

Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2015 - Q3 2016 74

Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 75

Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 79

Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 84

Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 87

Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 90

Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 93

Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 97

Figure 42: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 100

Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 103

Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 107

Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 111

Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 115

Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 118

Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 121

Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 124

Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2015 - Q3 2016 126
Deals in Pharmaceutical & Healthcare Industry Decreased in Q3 2016

GlobalData's 'Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q3 2016. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.

Number of M&A’s Decreased In Q3 2016

Merger and acquisition (M&A) deals, including asset purchases, recorded a decrease in the number of deals and deal values in Q3 2016 with 113 deals worth USD31.5 billion, compared to 273 deals worth USD75.1 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2016, compared to 135 deals worth USD96.1 billion in Q2 2016.

The central nervous system therapeutics market accounted for the majority of M&As with 145 deals worth USD66.6 billion between Q3 2015 and Q3 2016. Oncology therapeutics market followed in second place with 140 deals worth USD98.6 billion.

Partnerships Decreased In Q3 2016

Partnerships reported a marginal decrease in the number of deals and an increase in deal values with 192 deals worth USD4.5 billion in Q3 2016, compared to 197 deals worth USD3.3 billion in Q3 2015. On a quarter-on-quarter basis, the number of partnerships and their values decreased in Q3 2016, compared to 273 deals worth USD4.6 billion in Q2 2016.

Pharmaceutical and healthcare companies entered into 192 partnerships for Preclinical stage products, which accounted for 31% of the deals from Q3 2015 to Q3 2016. Products in Phase II stage stood second with 112 deals, which accounted for 18% of the deals.

Oncology therapeutics market recorded the highest value with USD11.1 billion deal value, USD1.8 billion milestone payments and USD981m upfront payments between Q3 2015 and Q3 2016, followed by the immunology market with USD10.1 billion in deal value, USD1.9 billion milestone payments and USD1.6 billion upfront payments.

Licensing Deals Repoted A Decline In Q3 2016

Licensing agreements reported a decrease in the number of deals and deal values in Q3 2016 with 138 deals worth USD10.2 billion in Q3 2016, as compared to 157 deals worth USD11.5 billion in Q3 2015. On a quarter-on-quarter basis, the number of licensing deals and their values decreased in Q3 2016, compared to 145 deals worth USD11.5 billion in Q2 2016.

Licensing agreements recorded a decrease in upfront payments and milestone payments in Q3 2016. A total of USD592.7m and USD5 billion were reported as upfront and milestone payments in Q3 2016, compared to USD707.5m and USD7.8 billion, respectively in Q3 2015. On a quarter-on-quarter basis, upfront payments and milestone payments decreased in Q3 2016, compared to USD1.1 billion and USD9.4 billion, respectively, in Q2 2016.

In licensing by phase, products in Preclinical stage recorded 175 deals, which accounted for 33% of the total deals between Q3 2015 and Q3 2016. In second place, products in Phase II accounted for 17% of the deals.

Venture Capital Investments Decreased In Q3 2016

The venture capital (VC) segment reported 174 deals worth USD2.1 billion in Q3 2016, as compared to 201 deals worth USD3.5 billion in Q3 2015. On a quarter-on-quarter basis, the number of VC deals and their values decreased in Q3 2016, compared to 197 deals worth USD2.4 billion in Q2 2016.

Orbimed Advisors, LLC topped the list of venture financing firms by participating in 33 transactions worth USD1.5 billion in the last five quarters (Q3 2015 - Q3 2016).

Deals In North America Reported A Decrease In Q3 2016

North America recorded a decrease in the number of deals and deal values in Q3 2016. The region registered 613 deals worth USD55.9 billion in Q3 2016, compared to 704 deals worth USD74.2 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2016, when compared to 708 deals worth USD132.2 billion in Q2 2016.

Europe recorded a decrease in the number of deals and deal values in Q3 2016 with 255 deals worth USD29.3 billion, as compared to 355 deals worth USD68.7 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals decreased and deal values increased in Q3 2016, when compared to 335 deals worth USD24.2 billion in Q2 2016.

Asia Pacific recorded a decrease in the number of deals and deal values in Q3 2016. The region reported 200 deals worth USD15.1 billion in Q3 2016, as compared to 267 deals worth USD21.3 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals and deal values decreased in Q3 2016, when compared to 222 deals worth USD16.5 billion in Q2 2016.

South and Central America and the Middle East and African regions, recorded a decrease in the number of deals and an increase in deal values in Q3 2016 with 156 deals worth USD38.5 billion, as compared to 167 deals worth USD21.3 billion in Q3 2015. On a quarter-on-quarter basis, the number of deals decreased marginally and deal values increased in Q3 2016, when compared to 157 deals worth USD18.5 billion in Q2 2016.

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus